These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6343310)

  • 1. Total body irradiation in chronic myeloid leukemia.
    Advani SH; Dinshaw KA; Nair CN; Ramakrishnan G
    Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):497-500. PubMed ID: 6343310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
    Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia.
    Kirshner J; Preisler HD; Raza A
    Am J Hematol; 1985 Feb; 18(2):191-200. PubMed ID: 3855599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regularities in the change in leukocyte count during treatment of chronic myeloid leukosis].
    Emanuél' NM; Sherman SI; Levitin EI; Rozanova LM; Evseenko LS; Kukharenko IuA
    Dokl Akad Nauk SSSR; 1967 Aug; 175(5):1197-200. PubMed ID: 5270825
    [No Abstract]   [Full Text] [Related]  

  • 6. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenic irradiation following chemotherapy in chronic myelogenous leukemia.
    Wilson JF; Johnson RE
    Radiology; 1971 Dec; 101(3):657-61. PubMed ID: 5288778
    [No Abstract]   [Full Text] [Related]  

  • 8. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis].
    Xu SX; Tang XH; Chen HQ; Feng B; Xu HQ; Chen XP; Tang XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1354-60. PubMed ID: 19099643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B.
    Silver RT; Mick R; Cooper R; Ellison RR; Levy R; Brunner K; Schwartz JM; Holland JF
    Cancer; 1987 Oct; 60(7):1442-8. PubMed ID: 3113712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Deeg HJ; Stevens EA; Salit RB; Ermoian RP; Fang M; Gyurkocza B; Sorror ML; Fatobene G; Baumgart J; Burroughs LM; Delaney C; Doney K; Egan DN; Flowers MED; Milano F; Radich JP; Scott BL; Sickle EJ; Wood BL; Yeung C; Storer BE
    Biol Blood Marrow Transplant; 2018 May; 24(5):956-963. PubMed ID: 29274396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimetabolites and pregnancy. Normal child born to a mother under treatment 8 years for chronic myeloid leukemia].
    Salmon M; Orsini A; Giraud F; Perrimond H; Gonggryp N
    Bull Acad Natl Med; 1972 Feb; 156(4):123-32. PubMed ID: 4629812
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.
    Nagler A; Savani BN; Labopin M; Polge E; Passweg J; Finke J; Kyrcz-Krzemien S; Volin L; Anagnostopoulos A; Aljurf M; Beelen DW; Vigouroux S; Milpied N; Suarez F; Mohty M
    Lancet Haematol; 2015 Sep; 2(9):e384-92. PubMed ID: 26685771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of chronic myelocytic leukemia.
    Galton DA
    Semin Hematol; 1969 Oct; 6(4):323-43. PubMed ID: 4900650
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
    Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
    Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
    Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
    Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Khalil MMI; Messner HA; Lipton JH; Kim DD; Viswabandya A; Thyagu S; Deotare U; Michelis FV
    Ann Hematol; 2018 Oct; 97(10):1975-1985. PubMed ID: 29947975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.